Company profile: Etna Biotech
1.1 - Company Overview
Company description
- Provider of vaccine and immunotherapeutic research and development for infectious diseases, with candidates targeting Hepatitis E, Congo Hemorrhagic fever, Leishmaniasis (Kala Azar), malaria, HPV (to prevent cervical cancer and genital warts), and seasonal and pandemic influenza.
Products and services
- Congo fever vaccine: Etna Biotech develops a candidate-stage vaccine engineered to prevent Congo Hemorrhagic fever, focusing on disease-specific immunization to reduce infection risk
- HPV vaccine: Etna Biotech engineers a candidate-stage HPV vaccine intended to prevent cervical cancer and genital warts by delivering prophylactic immunization
- Hepatitis E vaccine: Etna Biotech architects a candidate-stage Hepatitis E vaccine aimed at preventing infection, emphasizing targeted prophylaxis to curb disease incidence
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Etna Biotech
4-Antibody
HQ: Switzerland
Website
- Description: Provider of a human antibody drug-discovery platform focused on immuno-oncology, leveraging Retrocyte Display to generate therapeutic antibody candidates from human libraries expressed in mammalian B-lineage lymphocytes, and developer of a pipeline including Botensilimab (CTLA-4), Balstilimab (PD-1), Zalifrelimab (CTLA-4), AGEN2373 (anti-CD137), AGEN1571 (ILT-2) and ILT4 antagonists, with ongoing clinical trials across multiple cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4-Antibody company profile →
ImmuneXcite
HQ: United States
Website
- Description: Provider of a platform technology for enhancing the efficacy of therapeutic monoclonal antibodies for disease targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmuneXcite company profile →
Numab Therapeutics
HQ: Switzerland
Website
- Description: Provider of antibody-based therapeutics for severe diseases, including chronic inflammation and cancer, leveraging a plug-and-play platform to predictably yield ready-to-develop multispecific biotherapeutics. Offerings include NM26 for atopic dermatitis, NM49 for cancer, and λ-Cap (stable human antibody fragments) and MATCH (modular scaffolding for multispecific formats) technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Numab Therapeutics company profile →
Pulmotect
HQ: United States
Website
- Description: Provider of an inhaled therapeutic to prevent and treat respiratory infections. PUL-042 activates the innate immune system in the lungs to protect against viral, bacterial, and fungal pathogens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pulmotect company profile →
Apeiron Biologics
HQ: Austria
Website
- Description: Provider of discovery and development of novel cancer immunotherapies, with products including Qarziba (cancer immunotherapy, licensed to EUSAPharma), APN401 (first-in-class autologous cell therapy inhibiting the immune checkpoint Cbl-b using RNAi to treat solid tumors), and APN01 (inhaled treatment in clinical trials targeting SARS-CoV-2 in the respiratory tract).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apeiron Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Etna Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Etna Biotech
2.2 - Growth funds investing in similar companies to Etna Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Etna Biotech
4.2 - Public trading comparable groups for Etna Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →